Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human Study of Auger Molecular Therapy (AMT) in Patients With Malignant Cutaneous Lesions From Advanced Solid Tumors

NCT04807257 is registered in ClinicalTrials.gov with NanoRay Biotech Co., Ltd. as lead sponsor.

NCT NCT04807257
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04807257 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human Study of Auger Molecular Therapy (AMT) in Patients With Malignant Cutaneous Lesions From Advanced Solid Tumors
Lead sponsor
NanoRay Biotech Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 5, 2024
Completion date
December 31, 2026
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant fungating wound